Experience With Low-Dose Valganciclovir Prophylaxis in Adult Liver Transplant Recipients

Transplantation Proceedings

Volumn 39, Issue 10, 2007, Pages 3266-3270

  Dupuis, R ^a   Harris, M ^a   Gillis, K ^a   Gerber, D ^a   Fair, J ^a   Watson, R ^a   Koslowski, T ^a   Andreoni, K ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; GANCICLOVIR; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR; VIRUS ANTIGEN; VIRUS PROTEIN;

ADOLESCENT; ADULT; AGED; ANEMIA; ARTICLE; CYTOMEGALOVIRUS INFECTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GRAFT RECIPIENT; HIGH RISK PATIENT; HUMAN; LEUKOPENIA; LIVER TRANSPLANTATION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; ORTHOTOPIC TRANSPLANTATION; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT DURATION; VIREMIA; VIRUS DETECTION;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; CONTINENTAL POPULATION GROUPS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; FOLLOW-UP STUDIES; GANCICLOVIR; HUMANS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NORTH CAROLINA; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 37049017978     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2007.09.037     Document Type: Article

References (12)

1. Rubin R.H. The pathogenesis and clinical management of cytomegalovirus infection in the organ transplant recipient: the end of the "silo hypothesis". Curr Opin Infect Dis 20 (2007) 399
2. Fishman J.A., Emery V., Freeman R., et al. Cytomegalovirus in transplantation-challenging the status quo. Clin Transplant 21 (2007) 149
3. Cvetkocic R.S., and Wellington K. Valganciclovir. A review of its use in the management of CMV infection and disease in immunocompromised patients. Drugs 65 (2006) 859
4. Pescovitz M.D., Rabkin J., Merion R.B., et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemotherapy 44 (2000) 2811
5. Wiltshire H., Hirankarn S., Farrell C., et al. Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients. Clin Pharmacokinet 44 (2005) 495
6. Paya D., Humar A., Dominguez E., et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am Jour Transplanta 4 (2004) 611
7. Jain A., Orloff M., Kashyap R., et al. Does valganciclovir hydrochloride (Valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?. Transplant Proc 37 (2005) 3182
8. Park J.M., Arenas J.D., Fontana R.J., et al. Efficacy and safety of low dose valganciclovir for the prevention of cytomegalovirus disease in liver transplant recipients. Liver Transpl 12 (2005) 12
9. Roche. Valcyte (valganciclovir hydrochloride tablets). Product Information.
10. Johnson M., Zacks S., McIver P., et al. Randomized trial of oral ganciclovir plus cytomegalovirus (CMV) immune globulin (Ig) versus oral ganciclovir alone for CMV prophylaxis in liver and kidney transplant recipients. Am J Transplant 4 (2004) 535
11. Limaye A.P., Bakthavatsalam R., Kim H.W., et al. Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis. Transplantation 81 (2006) 1645
12. Wiltshire H., Paya C.V., Pescovitz M.D., et al. Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. Transplantation 79 (2005) 1477